北美冷冻注射药物市场报告 – 行业趋势和预测至2028年

市场分析与洞察：北美冻干注射药物市场

北美冻干注射药物市场预计将在 2021 年至 2028 年的预测期内实现市场增长。Data Bridge Market Research 分析，在 2021 年至 2028 年的预测期内，该市场以 5.7% 的复合年增长率增长，预计到 2028 年将达到 32.8361 亿美元。全球慢性健康状况的增加预计将成为推动冻干注射药物市场需求的驱动力。

冷冻干燥是冻干的另一个术语。这是一种通过在真空下冷冻和蒸发溶液来将固体物质从溶剂中分离出来的技术。冻干产品被认为比传统药物具有更长的保质期，因此受到青睐。生物制剂、蛋白质、抗体微生物、肠外、血浆、酶、诊断试剂、疫苗和营养保健品的保护通常通过冻干来完成。为了保持一些不稳定的散装成分稳定，需要对无菌注射剂进行冻干。

冻干注射药物技术进步日新月异，有望成为推动冻干注射药物市场需求的驱动力。冻干药物产品召回数量和包装类型的增加预计将成为冻干注射药物市场的限制因素。冻干药物监管批准的增加预计将成为推动冻干注射药物市场需求的机会。与制造用于肠外产品的冻干小瓶相关的因素预计将对冻干注射药物市场的需求构成挑战。

The lyophilized injectable drugs market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the lyophilized injectable drugs market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

North America Lyophilized Injectable Drugs Market scope and market size

The North America lyophilized injectable drugs market is categorized into seven notable segments which are based on the packaging, drug class, form, indication, route of administration, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

On the basis of packaging, the lyophilized injectable drugs market is segmented into vials, dual-chamber syringes, dual-chamber cartridges and others. In 2021, vials segment is expected to dominate the lyophilized injectable drugs market because the vials are most cost effective than other packaging.
On the basis of drug class, the lyophilized injectable drugs market is segmented into anti-infective, antineoplastic, diuretics, proton pump inhibitor, anesthetic, anticoagulant, NSAID’s, corticosteroids and others. In 2021, anti-infective segment is expected to dominate the lyophilized injectable drugs market because of the increased demand for the as anti-infective consists of various antibiotics which helps in preventing infection after the surgery.
On the basis of form, the lyophilized injectable drugs market is segmented into powder and liquid. In 2021, powder segment is expected to dominate the lyophilized injectable drugs market because of it is easy to transport and the chances of microbial growth are very less.
On the basis of indication, the lyophilized injectable drugs market is segmented into oncology, autoimmune diseases, hormonal disorders, respiratory diseases, gastrointestinal disorders, dermatological disorders, ophthalmic diseases and others. In 2021, oncology segment is expected to dominate the lyophilized injectable drugs market because of this disease is more and the R&D is more focused on developing drugs that are used for oncology.
On the basis of route of administration, the lyophilized injectable drugs market is segmented into intravenous/infusion, intramuscular and others. In 2021, intravenous/infusion segment is expected to dominate the lyophilized injectable drugs market because of the delivery rate is very high even the volume of the drug is very less.
根据最终用户，冻干注射药物市场分为医院、诊所、家庭医疗保健和其他。 2021 年，医院部门预计将在冻干注射药物市场中占据主导地位，因为与其他最终用户相比，这些机构可以获得更多的冻干药物。
根据分销渠道，冻干注射剂市场分为直接招标、零售销售和其他。 2021 年，直接招标部分预计将主导冻干注射剂市场，因为主要参与者大多与这些经销商建立联系以分销药品。

冻干注射药物市场国家级分析

对北美冻干注射药物市场进行了分析，并按国家、包装、药品类别、形式、适应症、给药途径、最终用户和分销渠道提供了市场规模信息。

北美冻干注射药物市场覆盖的国家包括美国、加拿大和墨西哥。

在北美，美国预计将主导冻干注射药物市场，因为癌症等疾病的增加导致对冻干药物的需求增加。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了北美品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀少的竞争而面临的挑战、销售渠道的影响。

制造商推出的新产品为冻干注射药物市场的参与者创造了新的机会

冻干注射药物市场还为您提供每个国家美容行业增长的详细市场分析，包括冻干注射药物市场销售、冻干注射药物市场发展的影响以及监管环境的变化及其对市场的支持。数据涵盖 2010 年至 2019 年的历史时期。

竞争格局和冻干注射药物市场份额分析

冻干注射药物市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对冻干注射药物市场的关注有关。

北美冻干注射剂市场的主要冻干注射剂供应商有 AuroMedics Pharma LLC Pharma LLC（Aurobindo Pharma 的子公司）、Astellas Pharma US, Inc.（Astellas Pharma Inc. 的子公司）、Aristopharma Ltd.、Pfizer Inc.、Viatris Inc.、Gilead Sciences, Inc.、Cirondrugs、Amneal Pharmaceuticals LLC、Jubilant Generics Limited – A Jubilant Pharma Company、Novartis AG、Otsuka America Pharmaceutical、Merck Sharp & Dohme Corp.（Merck & Co., Inc. 的子公司）、Fresenius Kabi USA（Fresenius Kabi AG 的子公司）、Sanofi、Celon Laboratories Pvt. Ltd. 和 Baxter 等。DBMR 分析师了解竞争优势，并为每个竞争对手分别提供竞争分析。

全球范围内的许多产品发布和协议也由公司发起，这也加速了冻干注射药物市场的发展。

例如，

2019 年 11 月，诺华公司宣布与美国制药公司 Medicines Company 达成战略协议。该公司达成的这项协议加强了其创新药物产品组合，从而增加了市场销售额和收入。
2021 年 3 月，Zydus Cadila 宣布降低其药物 Remdac 的成本，Remdac 是用于印度 COVID-19 患者的 Remdesivir 的仿制药。该公司采取的这一战略举措增加了其在市场上的需求和销量，从而提高了公司的信誉。

该公司推出的这款新产品增加了其在市场上的蛋白质估算组合。市场参与者的合作、合资企业和其他战略正在增强公司在冻干注射药物市场的市场，这也为组织改善其市场供应提供了好处。

SKU-63427

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

表格列表

TABLE 1 PIPELINE LYOPHILIZED INJECTABLE DRUGS

TABLE 2 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 3 NORTH AMERICA VIALS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 4 NORTH AMERICA DUAL-CHAMBER SYRINGES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 NORTH AMERICA DUAL-CHAMBER CARTRIDGES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 NORTH AMERICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 8 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 9 NORTH AMERICA ANTI-INFECTIVE’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 NORTH AMERICA ANTI-INFECTIVE’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 11 NORTH AMERICA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 12 NORTH AMERICA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 13 NORTH AMERICA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 14 NORTH AMERICA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 NORTH AMERICA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 16 NORTH AMERICA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 17 NORTH AMERICA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 18 NORTH AMERICA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 NORTH AMERICA PROTON PUMP INHIBITORS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 20 NORTH AMERICA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 NORTH AMERICA ANESTHETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 22 NORTH AMERICA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 NORTH AMERICA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 24 NORTH AMERICA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 NORTH AMERICA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 26 NORTH AMERICA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 NORTH AMERICA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 28 NORTH AMERICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 30 NORTH AMERICA POWDER IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 NORTH AMERICA LIQUID IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 33 NORTH AMERICA ONCOLOGY IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 NORTH AMERICA AUTOIMMUNE DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 NORTH AMERICA HORMONAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 NORTH AMERICA RESPIRATORY DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 NORTH AMERICA GASTROINTESTINAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 38 NORTH AMERICA DERMATOLOGICAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 39 NORTH AMERICA OPHTHALMIC DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 NORTH AMERICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 41 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 42 NORTH AMERICA INTRAVENOUS/INFUSION IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 43 NORTH AMERICA INTRAMUSCULAR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 NORTH AMERICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 45 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 46 NORTH AMERICA HOSPITAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 47 NORTH AMERICA CLINICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 48 NORTH AMERICA HOME HEALTHCARE IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 49 NORTH AMERICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 50 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 51 NORTH AMERICA DIRECT TENDER IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 52 NORTH AMERICA RETAIL SALES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 53 NORTH AMERICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 54 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 55 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 56 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 57 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 58 NORTH AMERICA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 59 NORTH AMERICA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 60 NORTH AMERICA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 61 NORTH AMERICA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 62 NORTH AMERICA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 63 NORTH AMERICA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 64 NORTH AMERICA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 65 NORTH AMERICA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 66 NORTH AMERICA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 67 NORTH AMERICA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 68 NORTH AMERICA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 69 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 70 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 71 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 72 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 73 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 74 U.S. LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 75 U.S. LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 76 U.S. LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 77 U.S. ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 78 U.S. ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 79 U.S. ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 80 U.S. ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 81 U.S. ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 82 U.S. DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 83 U.S. PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 84 U.S. ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 85 U.S. ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 86 U.S. NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 87 U.S. CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 88 U.S. LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 89 U.S. LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 90 U.S. LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 91 U.S. LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 92 U.S. LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 93 CANADA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 94 CANADA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 95 CANADA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 96 CANADA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 97 CANADA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 98 CANADA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 99 CANADA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 100 CANADA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 101 CANADA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 102 CANADA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 103 CANADA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 104 CANADA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 105 CANADA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 106 CANADA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 107 CANADA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 108 CANADA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 109 CANADA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 110 CANADA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 111 CANADA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 112 MEXICO LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 113 MEXICO LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 114 MEXICO LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 115 MEXICO ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 116 MEXICO ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 117 MEXICO ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 118 MEXICO ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 119 MEXICO ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 120 MEXICO DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 121 MEXICO PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 122 MEXICO ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 123 MEXICO ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 124 MEXICO NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 125 MEXICO CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 126 MEXICO LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 127 MEXICOLYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 128 MEXICO LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 129 MEXICO LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 130 MEXICO LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

图片列表

FIGURE 1 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: NORTH AMERICA VS. REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: MULTIVARIATE MODELLING

FIGURE 7 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: MARKET END USER COVERAGE GRID

FIGURE 11 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: SEGMENTATION

FIGURE 12 RISE IN CHRONIC HEALTH CONDITIONS IS EXPECTED TO DRIVE THE NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 VIALS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET

FIGURE 15 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, 2020

FIGURE 16 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, 2021-2028 (USD MILLION)

FIGURE 17 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, CAGR (2021-2028)

FIGURE 18 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, LIFELINE CURVE

FIGURE 19 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, 2020

FIGURE 20 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, 2021-2028 (USD MILLION)

FIGURE 21 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, CAGR (2021-2028)

FIGURE 22 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, LIFELINE CURVE

FIGURE 23 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, 2020

FIGURE 24 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, 2021-2028 (USD MILLION)

FIGURE 25 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, CAGR (2021-2028)

FIGURE 26 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, LIFELINE CURVE

FIGURE 27 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, 2020

FIGURE 28 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, 2021-2028 (USD MILLION)

FIGURE 29 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, CAGR (2021-2028)

FIGURE 30 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, LIFELINE CURVE

FIGURE 31 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 32 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

FIGURE 33 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)

FIGURE 34 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 35 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, 2020

FIGURE 36 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 37 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, CAGR (2021-2028)

FIGURE 38 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, LIFELINE CURVE

FIGURE 39 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 40 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 41 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 42 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 43 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: SNAPSHOT (2020)

FIGURE 44 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2020)

FIGURE 45 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2021 & 2028)

FIGURE 46 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2020 & 2028)

FIGURE 47 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING (2021-2028)

FIGURE 48 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY SHARE 2020 (%)

查看详细信息

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

What is the Growth Rate of the North America Lyophilized Injectable Drugs Market?

The North America Lyophilized Injectable Drugs Market Growth Rate Will be 5.7% by 2028.

How big is the North America Lyophilized Injectable Drugs Market?

The North America Lyophilized Injectable Drugs Market Will be worth USD 3,283.61 million by 2028.

What are the latest developments in the North America Lyophilized Injectable Drugs Market?

The latest developments in the North America Lyophilized Injectable Drugs Market are Novartis AG announced that it has undergone a strategic agreement with the Medicines Company, the U.S. based pharmaceutical companies, and Zydus Cadila announced that it has reduced the cost of its drug Remdac, a generic version of Remdesivir used for the COVID-19 patients in India.

What are the factors on which the North America Lyophilized Injectable Drugs Market Research is based on?

The packaging, drug class, form, indication, route of administration, end user, and distribution channel are the factors on which the North America Lyophilized Injectable Drugs Market Research is based.

Which are the major companies in the North America Lyophilized Injectable Drugs Market?

The major companies in the North America Lyophilized Injectable Drugs Market are AuroMedics Pharma LLC Pharma LLC (a subsidiary of Aurobindo Pharma), Astellas Pharma US, Inc. (a subsidiary of Astellas Pharma Inc.), Aristopharma Ltd., Pfizer Inc., Viatris Inc., Gilead Sciences, Inc., Cirondrugs, Amneal Pharmaceuticals LLC, Jubilant Generics Limited – A Jubilant Pharma Company, Novartis AG, Otsuka America Pharmaceutical, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Fresenius Kabi USA (a subsidiary of Fresenius Kabi AG), Sanofi, Celon Laboratories Pvt. Ltd. and Baxter etc.

北美冻干注射药物市场 – 行业趋势及 2028 年预测

北美冻干注射药物市场 – 行业趋势及 2028 年预测

市场分析与洞察：北美冻干注射药物市场

North America Lyophilized Injectable Drugs Market scope and market size

冻干注射药物市场国家级分析

竞争格局和冻干注射药物市场份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

报告

市场洞察

支持

解决方案

北美冻干注射药物市场 – 行业趋势及 2028 年预测

北美冻干注射药物市场 – 行业趋势及 2028 年预测

市场分析与洞察：北美冻干注射药物市场

North America Lyophilized Injectable Drugs Market scope and market size

冻干注射药物市场国家级分析

竞争格局和冻干注射药物市场份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

浏览相关页面